RxDoctor Payments Data

James Hermiller, MD

Interventional Cardiology · Indianapolis, INNPI 1619943263

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $188,051 of the $307,056 with a category attached, or 61.2%. 20 manufacturers reported payments, led by Abbott at 46.7% of the total. Reporting peaked in 2021 at $85,263 and has fallen 66.7% since, to $28,358 in 2025. Among interventional cardiology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$307,056in general payments, 2019–2025

Across 424 payments — averaging $724.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$143K
  • Edwards Lifesciences$102K
  • Medtronic$26K
  • Biotronik Inc.$10K
  • Livanova USA, Inc.$10K
  • Boston Scientific$6K
  • plus $10K from 14 others
$2,536,121in research payments, 2019–2025

Across 585 payments — averaging $4335.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$1.4M
  • Abbott$908K
  • Medtronic$124K
  • Boston Scientific$89K

What the payments were for

  • Consulting fees$188,05161%
  • Speaking & faculty fees$68,61322%
  • Grants$2,5001%
  • Travel & lodging$29,58910%
  • Food & beverage$18,2916%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$307,056 in reported general payments places this provider in the 95th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$209,216
Medicare patients
699
Services billed
1,542

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$274,193
EntrestoSacubitril/Valsartan56$82,516
XareltoRivaroxaban57$72,418
Repatha SureclickEvolocumab29$31,348
Nebivolol Hcl75$5,198
Metoprolol Succinate353$4,768
Ezetimibe211$4,324
Rosuvastatin Calcium375$3,603
Valsartan103$3,334
Carvedilol231$2,442
Atorvastatin Calcium275$2,282
ClopidogrelClopidogrel Bisulfate222$2,019
Amlodipine Besylate196$1,482
Torsemide71$1,339
Losartan Potassium159$1,303

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →